Richard Eglen discusses the use of organoids in drug discovery, including the screening of candidate compounds for efficacy, toxicity, and pharmacokinetics.
Richard Eglen discusses the use of organoids in drug discovery, including the screening of candidate compounds for efficacy, toxicity, and pharmacokinetics.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
